Stroke: the way things really are.
BACKGROUND
To comply with governmental requirements regarding the validity of therapeutic modalities and for medico-legal purposes, it is important to distinguish between what has been scientifically proven and what is anecdotal in the prevention and management of stroke.


RESULTS
This review summarizes the evidence for many of the modalities used to prevent stroke in high-risk patients, including antiplatelet drugs, anticoagulants, and endarterectomy, and the limitations of each. Controversial therapeutic modalities for which no scientific proof exists, such as anticoagulation of progressing stroke, are also discussed. The term "standard of care" should apply to modalities proven to be effective by scientifically controlled studies, not because they are used by many physicians. Treatment of acute stroke is still disappointing despite the development of many promising pharmacological strategies in experimental animals. An important part of the reason may be that the window of therapeutic opportunity is much shorter than the usual entry time of patients in most clinical trials. This logistic problem merits serious attention.


CONCLUSIONS
Numerous controlled, randomized, multiple-center clinical trials have demonstrated that the efficacy or lack thereof of various therapies directed at preventing or treating stroke can be determined and that anecdotal data may be misleading and harmful. At the least we should be aware of what we know and what we do not.
Scheinberg
P
P
Department of Neurology, University of Miami School of Medicine, Mount Sinai Hospital, Miami Beach, FL 33140.
D000925:Anticoagulants / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000517:prevention & control* / Q000601:surgery; D002985:Clinical Protocols; D016894:Endarterectomy, Carotid; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors